Pfizer and BioNTech Halt Major U.S. Covid Vaccine Trial Amid Low Enrollment

Pharmaceutical giants Pfizer and BioNTech have suspended a large-scale U.S. clinical trial for their updated Covid-19 vaccine targeting healthy adults aged 50 to 64. The companies cited a significant struggle in recruiting the 25,000 to 30,000 participants required to generate meaningful post-marketing data.

According to an internal letter dated March 30, all symptom monitoring for existing trial participants will cease after April 3.

This setback comes as vaccine manufacturers face stricter requirements from the U.S. Food and Drug Administration (FDA), which mandates large, placebo-controlled trials for this specific age group. Due to evolving pandemic trends and declining public interest in boosters, the enrollment process hit a standstill, leading to the early closure of the study.

In a joint statement, Pfizer and BioNTech emphasized that the decision was not driven by safety concerns or risk-benefit issues. Instead, the move is a pragmatic response to the inability to meet data collection targets. The FDA has been notified of the suspension, marking a challenging moment for the future approval and distribution of updated Covid-19 vaccines in the United States.